Newsroom

Industry News

1 Aug

Siyata Mobile Opens New Market Opportunity in France

Montréal, Québec – August 01, 2017 – Siyata Mobile Inc. (the “Company” or “Siyata”) (TSX-V:SIM / OTCQB:SYATF) is pleased to announce that it has opened a new market opportunity in France, receiving its first Purchase Order from SETMA SA (“SETMA”), a French based vehicle embedded electronics company. Founded in 1948, SETMA develops a wide range...

Read more

1 Aug

Mateon Therapeutics Completes Enrollment in Phase 2 Portion of FOCUS Study of CA4P for Platinum-Resistant Ovarian Cancer

Recruitment rate significantly increased following initial positive interim analysis Interim data read-outs expected in August (40 patients), September (60 patients) and November (80 patients) SOUTH SAN FRANCISCO, Calif., Aug. 01, 2017 (GLOBE NEWSWIRE) — Mateon Therapeutics, Inc. (MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment...

Read more

31 Jul

Intellipharmaceutics Intends to Vigorously Defend Recently Filed Purported Class Action Lawsuit

TORONTO, July 31, 2017 (GLOBE NEWSWIRE) — Intellipharmaceutics International Inc. (IPCI) (IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that on July 28, 2017, a purported class action complaint was...

Read more

31 Jul

Myomo, Inc. Obtains CE Mark Approval for MyoPro®

Enables Company to Start Providing Devices in Europe July 31, 2017 08:00 AM Eastern Daylight Time CAMBRIDGE, Mass.–(BUSINESS WIRE)–Myomo, Inc. (NYSE MKT:MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, today announced that it has obtained CE Mark approval for commercial sale of its next-generation MyoPro myoelectric...

Read more

31 Jul

Mateon Therapeutics Announces Positive Initial Data from Fifth Cohort of Phase 1b Study of OXi4503 in Relapsed/Refractory AML

Two patients of four (50%) achieved a complete remission No dose-limiting toxicities observed SOUTH SAN FRANCISCO, Calif., July 31, 2017 (GLOBE NEWSWIRE) — Mateon Therapeutics, Inc. (MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced preliminary data from the fifth dose...

Read more

31 Jul

Asterias Biotherapeutics to Report Second Quarter Results on August 14, 2017

FREMONT, Calif., July 31, 2017 (GLOBE NEWSWIRE) — Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that it will release second quarter 2017 financial and operational results on Monday, August 14, 2017 after the close of the U.S. financial...

Read more

28 Jul

Ascent Solar Demonstrates Breadth of Capabilities at the US Special Operations Command (SOCOM) Exclusive TE 17-3 Event in Washington, DC

THORNTON, CO–(Marketwired – Jul 28, 2017) – Ascent Solar Technologies, Inc. (OTCQB : ASTI ), a developer and manufacturer of state-of-the-art, lightweight, and flexible thin-film photovoltaic (PV) solutions, announces that the Company was one of 36 companies invited to demonstrate their breadth of capabilities at the US Special Operations Command’s (SOCOM) invitation-only...

Read more

27 Jul

Siyata Mobile Receives $3.9MM from Exercise of Warrants

MONTREAL, July 27, 2017 (GLOBE NEWSWIRE) — Siyata Mobile Inc. (the “Company” or “Siyata”) (TSX-V:SIM) (OTCQX:SYATF) is pleased to announce it has received ~$3.9MM from the exercise of 6.6M share purchase warrants (the “Warrants”). The funds will be used by the Company to continue its North American expansion throughout...

Read more

27 Jul

Moleculin Strengthens Board of Directors with Appointment of John M. Climaco

HOUSTON, TX–(Marketwired – July 27, 2017) – Moleculin Biotech, Inc., (MBRX)(“Moleculin” or the “Company”), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced the...

Read more

Page 5 of 250« First...34567...102030...Last »

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address